A Phase 4 interventional study of olanzapine and placebo in Bipolar I Disorder, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-06-03.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Whether treatment with olanzapine in combination with mood stabilizer reduces symptoms of both mania and depression more than treatment with mood stabilizer alone, in patients with a mixed episode of bipolar I disorder.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
olanzapine and divalproex
Drug: olanzapine · Drug: divalproex
placebo and divalproex
Drug: placebo · Drug: divalproex
15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
Also known as: LY170053, Zyprexa
placebo, capsules, by mouth every evening, daily, for 6 weeks.
dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint.
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline to endpoint (6 weeks)
Mean Change in Hamilton Depression Rating Scale-21 (HAMD) Scores From Baseline to Endpoint.
The 21-item HAMD measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60.
Time frame: Baseline to endpoint (6 weeks)
Number of Participants Meeting the Criteria for Mixed Onset of Action
The original outcome measure was Time to Mixed Onset of Action (at least a 25% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.
Time frame: Baseline to endpoint (6 weeks)
Number of Participants Meeting the Criteria for Mixed Response
The original outcome measure was Time to Mixed Response(at least a 50% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.
Time frame: baseline to endpoint (6 weeks)
Mean Change in Clinical Global Impression for Bipolar Illness Severity (CGI-BP) From Baseline to Endpoint
CGI-BP Severity is used by the clinician to record the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline to endpoint (6 weeks)
Number of Patients Hospitalized Due to Relapse of Mania or Depression.
Number of participants hospitalized as a result of relapse of mania or depression.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Laboratory Values - Fasting Cholesterol Change From Baseline
Change from Baseline to endpoint in cholesterol: value of cholesterol measure at endpoint minus the value at baseline.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Laboratory Values - Fasting Triglycerides Change From Baseline
Change from baseline to endpoint in triglycerides: Value of triglyceride measure at endpoint minus value at baseline.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Laboratory Values - Fasting Blood Glucose Change From Baseline
Change from baseline to endpoint in fasting blood glucose: Value of fasting blood glucose measure at endpoint minus value at baseline.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Laboratory Values - Bilirubin Total Change From Baseline
Change from baseline to endpoint in bilirubin total: Value of bilirubin total measure at endpoint minus value at baseline.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Vital Signs - Body Mass Index Change From Baseline
Change from baseline to endpoint in body mass index (an estimate of body fat derived by dividing body weight by height squared): Value of body mass index measure at endpoint minus value at baseline.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Vital Signs - Weight Change From Baseline
Change from baseline to endpoint: Value of weight measure at endpoint minus value at baseline.
Time frame: Baseline to endpoint (6 weeks)
Clinically Significant Vital Signs - Percentage of Participants With Baseline-to-Endpoint Weight Increase of at Least Seven Percent (7%)
Percentages of participants in each group who experienced an increase in weight of at least 7% from baseline to endpoint.
Time frame: Baseline to endpoint (6 weeks)
| Milestone | Olanzapine | Placebo |
|---|---|---|
| Started | 101 | 101 |
| Completed | 58 | 60 |
| Not completed | 43 | 41 |
| Withdrew: Lost to follow-up | 11 | 11 |
| Withdrew: Protocol entry criteria not met | 5 | 4 |
| Withdrew: Protocol violation | 8 | 7 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Physician decision | 2 | 4 |
| Withdrew: Sponsor decision | 4 | 5 |
| Withdrew: Lack of efficacy | 1 | 4 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: Death | 1 | 0 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint. | -10.15 ± 0.44 | -7.68 ± 0.44 |
The 21-item HAMD measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60.
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Mean Change in Hamilton Depression Rating Scale-21 (HAMD) Scores From Baseline to Endpoint. | -9.37 ± 0.55 | -7.69 ± 0.54 |
The original outcome measure was Time to Mixed Onset of Action (at least a 25% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.
| participants | Olanzapine | Placebo |
|---|---|---|
| Number of Participants Meeting the Criteria for Mixed Onset of Action | 81 (3 to 15) | 71 (4 to 45) |
The original outcome measure was Time to Mixed Response(at least a 50% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.
| participants | Olanzapine | Placebo |
|---|---|---|
| Number of Participants Meeting the Criteria for Mixed Response | 54 (9 to —) | 40 (13 to —) |
CGI-BP Severity is used by the clinician to record the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Mean Change in Clinical Global Impression for Bipolar Illness Severity (CGI-BP) From Baseline to Endpoint | -1.34 ± 0.11 | -1.06 ± 0.11 |
Number of participants hospitalized as a result of relapse of mania or depression.
| participants | Olanzapine | Placebo |
|---|---|---|
| Number of Patients Hospitalized Due to Relapse of Mania or Depression. | 1 | 0 |
Change from Baseline to endpoint in cholesterol: value of cholesterol measure at endpoint minus the value at baseline.
| milligrams per deciliter | Olanzapine | Placebo |
|---|---|---|
| Total Cholesterol Baseline | 191.37 ± 41.23 | 192.25 ± 44.45 |
| Total Cholesterol Change from Baseline | -7.80 ± 31.77 | -8.72 ± 28.80 |
| Low Density Lipoprotein Baseline (N=62,N=64) | 115.32 ± 38.82 | 111.01 ± 36.74 |
| Low Density Lipoprotein Change (N=62,N=64) | -9.22 ± 27.31 | -9.77 ± 28.05 |
| High Density Lipoprotein Baseline | 53.76 ± 12.03 | 51.48 ± 11.64 |
| High Density Lipoprotein Change from Baseline | -3.24 ± 10.02 | -1.22 ± 8.90 |
Change from baseline to endpoint in triglycerides: Value of triglyceride measure at endpoint minus value at baseline.
| milligrams per deciliter | Olanzapine | Placebo |
|---|---|---|
| Baseline | 111.46 ± 61.54 | 139.75 ± 77.22 |
| Change from Baseline | 22.91 ± 67.70 | 16.80 ± 73.25 |
Change from baseline to endpoint in fasting blood glucose: Value of fasting blood glucose measure at endpoint minus value at baseline.
| milligrams per deciliter | Olanzapine | Placebo |
|---|---|---|
| Baseline | 91.81 ± 11.98 | 91.90 ± 10.13 |
| Change from Baseline | 6.93 ± 23.72 | -0.55 ± 14.00 |
Change from baseline to endpoint in bilirubin total: Value of bilirubin total measure at endpoint minus value at baseline.
| micromoles per Liter | Olanzapine | Placebo |
|---|---|---|
| Baseline | 6.50 ± 3.46 | 6.65 ± 3.43 |
| Change from Baseline | -1.56 ± 2.99 | -0.74 ± 3.03 |
Change from baseline to endpoint in body mass index (an estimate of body fat derived by dividing body weight by height squared): Value of body mass index measure at endpoint minus value at baseline.
| kilograms per square meters | Olanzapine | Placebo |
|---|---|---|
| Clinically Significant Vital Signs - Body Mass Index Change From Baseline | 1.18 ± 0.12 | 0.26 ± 0.12 |
Change from baseline to endpoint: Value of weight measure at endpoint minus value at baseline.
| kilograms | Olanzapine | Placebo |
|---|---|---|
| Clinically Significant Vital Signs - Weight Change From Baseline | 3.34 ± 0.34 | 0.70 ± 0.34 |
Percentages of participants in each group who experienced an increase in weight of at least 7% from baseline to endpoint.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Clinically Significant Vital Signs - Percentage of Participants With Baseline-to-Endpoint Weight Increase of at Least Seven Percent (7%) | 22 | 3 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine | — | — | — |
| Placebo | — | — | — |
| Event | Olanzapine | Placebo |
|---|---|---|
| AstheniaGeneral disorders | 0/101 | 1/101 |
| Chest painGeneral disorders | 0/101 | 1/101 |
| DeathGeneral disorders | 1/101 | 0/101 |
| Acute hepatic failureHepatobiliary disorders | 1/101 | 0/101 |
| Head injuryInjury, poisoning and procedural complications | 1/101 | 0/101 |
| OverdoseInjury, poisoning and procedural complications | 0/101 | 1/101 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/101 | 0/101 |
| Skin lacerationInjury, poisoning and procedural complications | 0/101 | 1/101 |
| HypoaesthesiaNervous system disorders | 0/101 | 1/101 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/101 | 1/101 |
| Event | Olanzapine | Placebo |
|---|---|---|
| SedationNervous system disorders | 24/101 | 4/101 |
| Weight increasedInvestigations | 21/101 | 4/101 |
| SomnolenceNervous system disorders | 21/101 | 6/101 |
| Dry mouthGastrointestinal disorders | 13/101 | 3/101 |
| Increased appetiteMetabolism and nutrition disorders | 13/101 | 5/101 |
| FatigueGeneral disorders | 10/101 | 4/101 |
| TremorNervous system disorders | 9/101 | 0/101 |
| NasopharyngitisInfections and infestations | 4/101 | 7/101 |
| HeadacheNervous system disorders | 5/101 | 7/101 |
| Oedema peripheralGeneral disorders | 6/101 | 1/101 |
| Age Continuous(years) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 38.61 ± 11.20 | 38.52 ± 11.07 | 38.56 ± 11.11 |
| Sex: Female, Male(Participants) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Female | 61 | 58 | 119 |
| Male | 40 | 43 | 83 |
| Region of Enrollment(participants) | Olanzapine | Placebo | Total |
|---|---|---|---|
| United States | 101 | 101 | 202 |
| Race/Ethnicity(participants) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Caucasian | 46 | 56 | 102 |
| African Descent | 38 | 29 | 67 |
| Hispanic | 15 | 13 | 28 |
| Native American | 1 | 2 | 3 |
| East Asian | 1 | 1 | 2 |
| Body Mass Index (BMI)(kilograms per square meters) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 30.73 ± 8.99 | 31.72 ± 8.29 | 31.23 ± 8.64 |
| Body Weight(kilograms) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 87.33 ± 24.17 | 90.75 ± 23.70 | 89.04 ± 23.94 |
The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine